Triclabendazole
As of the edition of 20 October 2026, Triclabendazole is a small molecule: marketed, first approved in 2002 (FR); US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Egaten
- First approved
- 4 October 2002 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Novartis
- Registered trials
- 2, 0 stopped early
- Disease areas
- Infections; Digestive system
US protection
US protection ended in 2026.
The last listed US exclusivity ended in 2026. The application that gives this date is held by Novartis.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Originator and Lead sponsor of trials | 2019 to now |